Danisco has invested EUR600m (US$847m) in the company in a bid to add more than 2,000 tonnes to its existing cultures production capacity in the next three years.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Danish food ingredients company said today (18 August) that the investments will meet growing global demand for frozen and freeze-dried Direct Vat Inoculants (DVI) and reinforce its leading market position as a cultures supplier.
The additional capacities will be located both in North America, where Danisco is transforming a former enzyme production unit from its Genencor Division into a cultures plant, and in Europe.
“We will accelerate our time-to-market to better serve our DVI customers using our production hubs in Europe and in the US,” said Doug Willrett, executive vice president, Danisco cultures division.
The company said it has already “debottlenecked” its capacity at several cultures production sites within the past year. The around 2,000 tonnes additional capacity is expected to progressively be commissioned over the next three years and will benefit from the latest process improvements developed by Danisco.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Rochester’s transformation into a cultures plant will enable us to save on time and capital expenditures and be ready in the US during the course of 2009,” said Willrett.
“This is a significant investment from Danisco, which demonstrates the group’s long term commitment to be our customers’ first choice for their needs in state-of-the-art, affordable cultures,” added Fabienne Saadane-Oaks, Danisco bio actives president.
